TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

S-195396

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
Los Alamos National Laboratory (LANL), operating under the Department of Energy and managed by TRIAD (DOE Contractor), has issued a special notice regarding a technology licensing opportunity for the Clathrate Therapeutics Platform. This innovative platform is designed to address longstanding challenges in the clinical application of therapeutic gas-based treatments, specifically focusing on improving safety, precision, and effectiveness through controlled, localized delivery at the site of disease. The Clathrate Therapeutics Platform leverages a proprietary controlled-release system that temporarily stabilizes therapeutic gases within a biocompatible structure. This structure enables gradual, sustained release under physiological conditions, ensuring targeted exposure at the intended treatment site while minimizing systemic dispersion. The technology is further enhanced by an integrated computational modeling capability, which supports optimization of dosing profiles and treatment parameters, thereby reducing technical risk and accelerating development timelines prior to in vivo studies. Key objectives of this licensing opportunity include enabling programmable, targetable, and commercially viable gas-based therapies across high-value clinical markets such as oncology, cardiovascular care, neurology, and regenerative medicine. The platform’s versatility allows for integration with drug-device combinations and existing treatment modalities, making it suitable for a wide range of applications in the pharmaceutical, medical device, biotechnology, and computational drug development sectors. Expected deliverables for licensees include access to the patented and patent-pending technology (US patent pending, reference LA-UR-26-22810), as well as the opportunity to leverage LANL’s predictive modeling tools for treatment optimization. The technology is currently at Technology Readiness Level (TRL) 2, indicating early-stage development with demonstrated concept and initial proof-of-principle. The contracting entity is TRIAD, a federal office under the Department of Energy, with the place of performance located in Los Alamos, New Mexico. The opportunity is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). There are no set-aside requirements associated with this notice, making it open to all interested parties. LANL’s licensing program is structured to facilitate the transition of laboratory-developed inventions to commercial innovations through exclusive and non-exclusive licensing agreements. This notice is not a solicitation for external development services; rather, it is an invitation for companies to license and further develop the Clathrate Therapeutics Platform. Interested parties are encouraged to contact Caleb Ledgerwood or Lindsay Augustyn at [email protected] for specific discussions regarding licensing arrangements. For additional information, prospective licensees can visit the LANL technology licensing portal at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology or search available technologies at m.lanl.gov/tech-search. The notice remains active, with a response deadline of April 12, 2026. This opportunity is particularly relevant for organizations seeking to advance gas-based therapeutics, enhance combination treatment strategies, and accelerate the translation of novel therapies into clinical practice. The platform’s differentiated capabilities and partnership-ready architecture position it as a scalable solution for unlocking new commercial opportunities in areas where gas-based therapeutics have previously faced delivery limitations. Primary Contact: Caleb Ledgerwood ([email protected]) Secondary Contact: Lindsay Augustyn ([email protected]) Notice URL: https://sam.gov/opp/49e123ce2cd844449f09820f7b1c9ac1/view Contractors evaluating this opportunity should consider their capacity for pharmaceutical development, medical device integration, and computational modeling, as well as their interest in pioneering new therapeutic modalities in collaboration with a leading national laboratory.